menu
    • menu
    [{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"AIV001","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"AIV001","moa":"VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AiViva Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AiViva Biopharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by AiViva Biopharma

    Menu

    AiViva Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenvatinib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AiViva Completes Enrollment in Phase 1 Trial of AIV007 for Macular Degeneration

                            Details : AIV007 is a novel prolonged drug release formulation. It targets VEGFR, PDGFR, and FGFR to address macular degeneration and diabetic macular edema.

                            Brand Name : AIV007

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 26, 2024

                            Lead Product(s) : Lenvatinib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenvatinib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AiViva Completes Enrollment in Phase 1 Trial of AIV007 for Macular Diseases

                            Details : AIV007 is a novel prolonged drug release formulation. It targets VEGFR, PDGFR, and FGFR to address macular degeneration and diabetic macular edema.

                            Brand Name : AIV007

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 23, 2024

                            Lead Product(s) : Lenvatinib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Axitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin...

                            Details : AIV001 (axitinib) is a novel intradermally administered product designed for local, prolonged treatment effect for dermatological conditions. Now it has completed phase 1/2 clinical trials for the treatment of patients with nonmelanoma skin cancer.

                            Brand Name : AIV001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 11, 2023

                            Lead Product(s) : Axitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenvatinib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic ...

                            Details : AIV007 is a novel formulation using our JEL™ Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis.

                            Brand Name : AIV007

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 22, 2023

                            Lead Product(s) : Lenvatinib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AIV001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AiViva Biopharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer

                            Details : Second clinical trial assessing AIV001 to address unmet needs of skin diseases building on the exploratory efficacy of AIV001 in an earlier trial in wound healing from surgical incision. AIV001 to be tested in patients with superficial or nodular basal c...

                            Brand Name : AIV001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 02, 2020

                            Lead Product(s) : AIV001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            AiViva Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AIV001

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AiViva Biopharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Woun...

                            Details : AIV001 was shown to be safe and well tolerated after local intradermal treatment of incisional wounds. Reduction in fibrosis was observed from single AIV001 treatment post-wounding.

                            Brand Name : AIV001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 25, 2020

                            Lead Product(s) : AIV001

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth